New combo therapy targets liver cancer that stopped responding to standard drug

NCT ID NCT01840592

First seen May 07, 2026 ยท Last updated May 07, 2026

Summary

This study tests whether adding a chemotherapy drug (doxorubicin) to the standard drug sorafenib can help people with advanced liver cancer whose disease has worsened while on sorafenib alone. About 30 adults with confirmed liver cancer and good liver function are participating. The goal is to see if the combination improves survival and slows tumor growth, while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center at Basking Ridge

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center at Mercy Medical Center

    Rockville Centre, New York, 11570, United States

  • Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center

    Sleepy Hollow, New York, 10591, United States

  • Memorial Sloan Kettering West Harrison

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.